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Fluid and Electrolyte Disturbances in Critically Ill 
Patients
Disturbances in fluid and electrolytes are among the most common clinical 
problems encountered in the intensive care unit (ICU). Recent studies have 
reported that fluid and electrolyte imbalances are associated with increased 
morbidity and mortality among critically ill patients. To provide optimal care, 
health care providers should be familiar with the principles and practice of fluid 
and electrolyte physiology and pathophysiology. Fluid resuscitation should be 
aimed at restoration of normal hemodynamics and tissue perfusion. Early goal-
directed therapy has been shown to be effective in patients with severe sepsis 
or septic shock. On the other hand, liberal fluid administration is associated 
with adverse outcomes such as prolonged stay in the ICU, higher cost of care, 
and increased mortality. Development of hyponatremia in critically ill patients 
is associated with disturbances in the renal mechanism of urinary dilution. 
Removal of nonosmotic stimuli for vasopressin secretion, judicious use of 
hypertonic saline, and close monitoring of plasma and urine electrolytes are 
essential components of therapy. Hypernatremia is associated with cellular 
dehydration and central nervous system damage. Water deficit should be 
corrected with hypotonic fluid, and ongoing water loss should be taken into 
account. Cardiac manifestations should be identified and treated before initiating 
stepwise diagnostic evaluation of dyskalemias. Divalent ion deficiencies such 
as hypocalcemia, hypomagnesemia and hypophosphatemia should be identified 
and corrected, since they are associated with increased adverse events among 
critically ill patients.
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mechanisms include reduced perfusion to the kidney due 
to hypovolemia or hypotension; activation of hormonal 
systems such as renin-angiotensin-aldosterone system 
and vasopressin; and tubular damage caused by ischemic 
or nephrotoxic kidney damage, including renal insult 
caused by a myriad of medications used in the intensive 
care. In addition, inappropriate administration of fluid 
Introduction
Fluid and electrolyte disorders are among the most 
common clinical problems encountered in the setting 
of intensive care. Critical disorders such as severe burns, 
trauma, sepsis, brain damage, and heart failure lead to 
disturbances in fluid and electrolyte homeostasis. Possible Electrolyte Blood Press 8:72-81, 2010 • doi: 10.5049/EBP.2010.8.2.72    73
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and electrolytes should be considered in the diagnosis and 
treatment of fluid and electrolyte disturbances. 
This article is intended to provide readers with relevant 
information on fluid and electrolyte problems frequently 
found in the intensive care unit (ICU), as well as on 
medications associated with fluid and electrolyte disorders. 
Fluid management
Volume resuscitation of a patient with hypovolemic 
shock or sepsis is an essential component of patient 
care. Massive amounts of intravenous fluid are usually 
administered to replace intravascular volume deficit and 
to minimize complications attributed to hypovolemia 
such as tachycardia, hypotension, acute kidney injury, and 
multiorgan failure. Goal-directed therapies focused on 
restoration of normal blood pressure and organ perfusion 
have been advocated in the management of critically ill 
patients. Early goal-directed therapy, which is instituted 
in the initial phase of management of patients with severe 
sepsis or septic shock, has been shown to improve overall 
survival
1). Clinicians should bear in mind that assessment 
of hemodynamic response to volume resuscitation and 
vasopressors should be based on specific hemodynamic and 
oxygenation parameters such as mean arterial pressure, 
central venous pressure, and central venous oxygen 
saturation, not solely on symptoms and physical findings. 
In contrast to the notion of aggressive and liberal volume 
resuscitation, a growing body of evidence strongly suggests 
that fluid overload may be detrimental to critically ill 
patients. Relatively little attention has been paid to the 
consequences of fluid overload such as respiratory failure, 
increased cardiac demand, and peripheral edema. Recent 
studies on patients with acute lung or kidney injury have 
reported that fluid overload has been associated with 
adverse outcomes
2-4). Although uniform definitions of fluid 
overload and well-designed randomized clinical trials are 
lacking, there seems to be a need to avoid overzealous fluid 
resuscitation in a subset of patients
5). 
As a general rule, daily input and output of fluid should 
be closely monitored, and loss into “third spaces” should 
be taken into account. Vital signs, findings from physical 
examination, and chest radiographs are of great importance 
in assessing the volume status of the patient. Invasive 
monitoring of central venous pressure or pulmonary 
capillary wedge pressure may be useful. Novel techniques 
involving invasive monitoring of extracellular fluid volume 
have been proposed, but none of them have been rigorously 
validated in clinical care
6). 
Hyponatremia
Disturbances in plasma sodium concentrations are a 
common clinical problem in patients admitted to the 
intensive care unit. Many cases of dysnatremia are acquired 
after a patient is admitted to the ICU, and the presence of 
dysnatremia is associated with poor prognosis. A recent 
study involving 151,486 adult patients from 77 intensive 
care units over a period of 10 years has demonstrated that 
many cases of dysnatremia are acquired in the intensive 
care unit, and that the severity of dysnatremia is associated 
with poor outcome in a graded fashion
7). Another study 
on the ICU patients with dysnatremias corroborated these 
findings, reporting that ICU-acquired hyponatremia 




+] represents a relative water excess in 
conjunction with impaired ability of the kidney to excrete 
electrolyte-free water. Removal of excess water by the 
kidney requires urinary dilution, which is compromised 
in virtually all patients in the ICU: (1) Heart failure, sepsis, 
shock, and multiple organ dysfunction syndrome impair 
glomerular filtration and enhance sodium and water 
reabsorption at the proximal tubule, thereby diminishing 
delivery of the filtrate to the diluting segment, i.e., the 
thick ascending limb of the loop of Henle and the distal 
convoluted tubule; (2) loop diuretics, thiazides, osmotic 
diuretics, and tubulointerstitial pathology reduce the 
reabsorption of sodium and chloride in the diluting 
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production such as pain, nausea, medications, and hypo-
volemia lead to increased water reabsorption in the 
collec  ting duct. In addition to impaired urinary dilution, 
hyponatremia in the critical care setting is related to 
inappropriate administration of hypotonic fluid
9).
Symptoms of hyponatremia occur most commonly 
with a rapid decrease in plasma [Na
+] to < 125 mEq/
L. Seizure and coma usually result from rapid decrease 
in plasma [Na
+] to < 110 mEq/L. The most dreaded 
complication in a patient with symptomatic hyponatremia 
is acute cerebral edema. Risk factors for development of 
acute cerebral edema should be identified before initiating 
therapy, including hypoxia, postoperative premenopausal 
women, elderly women on thiazide diuretics, polydipsic 
patients, children, and marathon runners
10). Symptoms 
of hyponatremia may not be apparent in ventilated and 
sedated patients in the ICU, and worsening of cerebral 
edema may lead to catastrophic consequences such as 
brainstem herniation and respiratory arrest.
The time of development of hyponatremia and the 
presence of symptoms should dictate the management 
of hyponatremia. Correction of plasma [Na
+] should 
be undertaken without delay in symptomatic patients, 
particularly those experiencing seizures. Development of 
hyponatremia in less than 48 hours and the presence of 
symptoms strongly suggest that the benefit of treating acute 
cerebral edema outweighs the risk of treatment-associated 
adverse effects. Hypertonic sodium chloride with or 
without a loop diuretic is usually started at a rate of 1–2 
mL/kg/hr to raise sodium concentration by 1–2 mEq/L/hr. 
This rapid correction of hyponatremia should be limited to 
the initial phase of management. The overall correction of 
[Na
+] should not exceed 8–12 mEq/L for 24 hours, as the 
risk of osmotic demyelination rises above this limit. 
Estimated change in plasma [Na
+] following the admini-
stration of 1 L of an intravenous fluid regimen can be 
calculated by equations proposed by Madias and Adrogue 
as follows:
Change in plasma [Na
+] = 
Infusate [Na
+] – plasma [Na
+]
Total body water + 1
Change in plasma [Na
+] = 
Infusate [Na
+] + infusate [K
+] – plasma [Na
+]
Total body water + 1
These equations have been shown to accurately predict 
changes in plasma [Na
+] under most clinical settings with 
a tendency to underestimate the achieved plasma [Na
+], 
sometimes by significant amounts
11, 12). An important caveat 
to be remembered is that these equations assume human 
body as a closed system and therefore do not take into 
account ongoing fluid and electrolyte gain or loss. Thus, a 
cornerstone of therapy is close monitoring of symptoms, 
amount of fluid given to the patient, urine output, and 
plasma and urine electrolytes. 
Euvolemic asymptomatic hyponatremia does not require 
urgent therapy, since the absence of symptoms indicates that 
brain cells have adapted to hypoosmolality. Identification 
and removal of reversible causes should be the first step of 
management.
Hypovolemic hyponatremia results from the loss of both 
water and solutes, with a greater relative loss of solutes. It is 
typically observed in a patient who was on a low-salt diet 
and was taking thiazide as an antihypertensive medication. 
Withdrawal of thiazide and replacement of volume deficit 
remove the stimulus for vasopressin release and initiate 
water diuresis. Plasma [Na
+] should be closely monitored, 
since the onset of water diuresis may herald an abrupt 
rise in plasma [Na
+]. In this regard, the initial choice of 
intravenous fluid should be 0.9% sodium chloride, unless 
the patient is symptomatic or hyponatremia is documented 
to have developed acutely (< 48 hours).
Hypervolemic hyponatremia occurs when both water 
and solute are retained in the body, but water is increased to 
a greater extent. Many cases of hypervolemic hyponatremia 
are associated with severe and sometimes irreversible 
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underlying disorders, restriction of both water and sodium 
intake, and administration of loop diuretics are helpful. 
Severe hyponatremia in patients with decompensated heart 
failure may require extracorporeal ultrafiltration, which 
has been consistently shown to improve congestion, lower 
diuretic requirements, and correct hyponatremias
13). 
To avoid osmotic demyelination during the treatment of 
hyponatremia, the rate of correction of plasma [Na
+] should 
be less than 8–12 mEq/L/day. Patients who are at greater 
risk of developing osmotic demyelination include alcoholics, 
malnourished patients, hypokalemic patients, burn patients, 
patients with previous hypoxic episodes, elderly women on 
thiazide diuretics, and patients with plasma [Na
+] < 105 
mEq/L
10).
Although V2 receptor antagonists are a useful option for 
management of euvolemic and hypervolemic hypo  natremia, 
their use is associated with high cost of care, development 
of thirst which makes correction of hyponatremia more 
difficult, and the risk of rapid rise of plasma [Na
+]. 
Hypernatremia
Patients in the ICU are at a high risk of developing hyper-
natremia. Predisposing factors include the administration of 
sodium bicarbonate solutions to correct metabolic acidosis; 
renal water loss through a concentrating defect from renal 
disease or the use of diuretics or solute diuresis from glucose 
or urea; gastrointestinal fluid losses through nasogastric 
suction and lactulose administration, and water losses 
through fever, drainages, and open wounds. Acute diabetes 
insipidus with hypernatremia can complicate traumatic 
brain injury, occurring within 5–10 days after brain injury 
and disappearing within a few days to 1 month
14). 
Detection and treatment of hypernatremia require 
recognition of symptoms, identification of the underlying 
defects of water metabolism, correction of volume dis-
tur  bances, and correction of hypertonicity. Primary 
manifestations are changes in mental status, including rest-
lessness, irritability, lethargy, confusion, and somnolence. 
Patients may complain of intense thirst if they can com-
municate. Polyuric patients should undergo evaluation 
for defects in urinary concentration because previous 
knowledge of such disorders allows clinicians to adequately 
replace urinary water loss and avert the development of 
serious hypernatremia. Determination of urinary osmole 
excretion rate is helpful in differentiating water diuresis 
from solute diuresis. Patients at risk of developing diabetes 
insipidus include those with central nervous system disease 
and those receiving lithium or amphotericin B. 
The rate of correction of hypernatremia depends on its 
rate of development and on the presence of symptoms. 
It is generally recommended that half of the water deficit 
be replaced in 12 to 24 hours as the neurological status is 
carefully monitored. The remaining deficit can be cor  rected 
during the next 48 hours. The maximum rate of plasma 
[Na
+] decrease should not exceed 2 mEq/L/hr. Prescribed 
rate of correction can be lowered with improvement in 
symptoms. Ongoing loss of water during the course of 
treatment should be accounted for in the course of treat-
ment. It is safe to measure plasma and urine electrolyte 
every one or two hours in the initial phase of management.
Hypervolemic hypernatremia is not uncommon and 
often iatrogenic, particularly in patients who receive 
large amount of saline or bicarbonate in the course of 
their illness. Treatment of hypervolemic hypernatremia 
requires removal of excess sodium from the body. Exo-
genous source of sodium should be eliminated unless 
clinically indicated. Loop diuretics with replacement of 
free water may be helpful in inducing negative sodium 
balance. Because hypervolemic hypernatremia is often an 
iatrogenic complication that develops only if renal function 
is compromised, renal replacement therapy is usually the 
only effective treatment in this setting. Composition of 
hemodialysis solution should be adjusted to lower sodium 
concentration. In terms of prevention, a rising plasma 
[Na
+] should be regarded as a contraindication to further 
administration of saline, and should prompt treatment with 
hypotonic fluid via oral or parenteral route. 
In treating patients with hypovolemic hypernatremia, 
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be done before the replacement of water deficit, especially 
in patients with hypotension and obvious signs of hypo-
volemia. Isotonic sodium chloride should be given, and the 
underlying cause of volume loss should be identified and 
corrected. Treatment of euvolemic hypernatremia should be 
focused on repleting water deficit and decreasing ongoing 
loss of hypotonic fluids. 
  Hypokalemia
Major causes of hypokalemia include low dietary 
potassium intake, shift into the intracellular compartment, 
extrarenal potassium loss, and renal potassium loss. Medi-
cations commonly prescribed in the ICU are associated 
with hypokalemia
9). Sympathomimetics, insulin, methylx-
anthines, and dobutamine drive extracellular potassium 
into cells by stimulating Na
+,K
+-ATPase. Diuretics increase 
renal potassium loss by inhibiting sodium reabsorption in 
the loop of Henle and in the distal nephron. Amphotericin 
B is well known for its capability of disrupting the function 
of the collecting duct, causing nephrogenic diabetes 
insipidus, renal potassium loss, and distal renal tubular 
acidosis. Nonreabsorbable anions such as some penicillins 
and aminoglycosides can cause hypokalemia via obligatory 
potassium loss into urine. 
Signs and symptoms of hypokalemia are largely neu-
ro  muscular, including paralysis, weakness, nausea, 
vomiting, constipation, respiratory muscle weakness, and 
rhabdomyolysis. The most dreaded complications related to 
hypokalemia are cardiac arrhythmias, especially in patients 
with hypertension, myocardial infarction/ischemia, or 
heart failure. Electrocardio-graphic changes seen in patients 
with hypokalemia include ST-segment depression, T-wave 
flattening, T-wave inversion, and the presence of U waves. 
In the initial approach to the patient with hypokalemia, 
the major objectives are to rule out an emergency for which 
therapy must take precedence. The presence of respiratory 
muscle paralysis or changes in electrocardiogram should 
prompt a clinician to begin emergent therapy. If emergent 
settings are not present, the basis for hypokalemia should 
be sought by assessing the rate of urinary potassium 
excretion. If it is appropriately low (i.e., 24-hour urine K
+ 
< 20 mEq/day or random urine K
+/creatinine < 15 mEq/
g or 1.5 mEq/mmol), transcellular shift or extrarenal K
+ 
loss should be suspected. If urinary K
+ excretion is high, 
transtubular potassium gradient (TTKG), acid-base status, 
and the presence or absence of hypertension are helpful 
in differential diagnosis of hypokalemia due to renal 
potassium loss. A TTKG larger than 4 suggests that there is 
an increase in K
+ secretion into the cortical collecting duct, 
i.e., a high K
+ concentration in the cortical collecting duct. 
Except for emergent settings, oral administration of 
potassium is always preferred. Replacement of potassium 
via parenteral route should be reserved for patients with 
severe hypokalemia presenting with electrocardiographic 
abnormalities. Rapid infusion of potassium (i.e., > 10–20 
mEq/hr) requires a central venous catheter, as infusion via 
a peripheral line causes phlebitis and vein injury. Amount 
of the initial dose should be in the range of 40–80 mEq. 
Total amount of daily K
+ replacement should be less than 
240–400 mEq/day. Parenteral K
+ replacement should be 
given in the form of dextrose-free vehicles, as dextrose 
infusion induces insulin secretion and prevents rapid 
correction of extracellular K
+ deficit. Hypocalcemia and 
hypomagnesemia should be identified and corrected if 
hypokalemia persists despite adequate supplementation.
Hyperkalemia
Renal failure, adrenal insufficiency, insulin deficiency 
and resistance, and tissue damage from rhabdomyolysis, 
burns, or trauma are predisposing factors for hyperkalemia 
in critically ill patients. A lot of medications used in the 
ICU can also cause hyperkalemia, including beta-blockers, 
inhibitors of renin-angiotensin-aldosterone system, po-
tassium-sparing diuretics, heparin and its derivatives, 
trimethoprim, and non-steroidal anti-inflammatory drugs. 
Succinylcholine is a depolarizing muscle relaxant fre-
quently used in the intensive care. It binds to the nitoconic 
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and depolarizes muscle membrane by inducing Na
+ and 
Ca
2+ influx into and K
+ efflux out of myocytes. Critical 
illness and anatomical or functional denervation of 
muscle result in (1) increased distribution of acetylcholine 
receptors throughout the muscle membrane beyond the 
neuromuscular junction, (2) altered subunit composition of 
acetylcholine receptors, and (3) the expression of a newly 
identified class of acetylcholine receptors which have longer 
duration of potassium efflux into the extracellular fluid
15). 
As a result, the use of succinylcholine in critically ill patients 
is associated with higher potential for precipitating acute 
hyperkalemia. The risk of hyperkalemia is particularly 
higher in patients with upper or lower motor neuron 
defects, functional or chemical denervation (e.g., muscle 
relaxants, hypermagnesemia, clostridial toxins), direct 
muscle trauma, and severe infection or inflammation
15).
In the absence of life-threatening conditions such as 
ventricular arrhythmia, initial diagnostic and thera-
peutic attempt should be focused on exclusion of pseu-
dohyperkalemia, identification of the source of transcellular 
potassium shift, and discontinuation of medications 
potentially associated with hyperkalemia. The next 
diagnostic step is to assess urinary potassium excretion, 
which should be high in the face of high extracellular [K
+] 
if renal function is not compromised (i.e., > 200 mEq/
day or 140 μmol/min). If there is relatively low urinary K
+ 
excretion, calculation of TTKG should follow to determine 
the cause of impaired renal K
+ excretion. A low TTKG 
may warrant the administration of 9α-fludrocortisone to 
differentiate between aldosterone deficiency and resistance 
to aldosterone.
Treatment strategy of hyperkalemia depends on the 
presence of emergent conditions. If any electrocardiographic 
abnormality attributable to hyperkalemia is present, emer-
gency management should take precedence over diagnostic 
evaluation. Intravenous calcium gluconate is the first step 
of management to antagonize the depolarizing effect of 
hyperkalemia. The next step should be to facilitate the 
shift of potassium into intracellular compartment. Insulin 
with 50% glucose is most effective as it is associated with 
most rapid and biggest drop in plasma [K
+]. Intravenous or 
inhaled albuterol may be used. Sodium bicarbonate should 
be avoided in patients with extracellular fluid volume 
overload and is usually not the first choice in the treatment 
of hyperkalemia, as data on the usefulness of sodium 
bicarbonate are equivocal
16). 
After acute management, long-term therapy of hyper-
kalemia should include the removal of potassium from the 
body. Dialysis is an effective modality, especially for patients 
with renal failure. Sodium polystyrene sulfonate is slow 
to exert potassium-lowering effect, and can cause sodium 
retention and bowel necrosis. Sources for potassium excess 
such as muscle injury and tissue ischemia should be sought 
and treated appropriately.
Hypophosphatemia
Hypophosphatemia has been associated with critical 
conditions such as Gram-negative sepsis and open heart 
surgery
17-19). The prevalence of hypophosphatemia is 
high in the ICU, reported to be observed in about 28% 
in critically ill patients
20). Hypophosphatemia (plasma 
phosphate concentration < 2.5 mg/dL or 0.81 mmol/L) 
may result from decreased intestinal phosphate absorption, 
increased renal phosphate losses, and a shift of phosphate to 
intracellular space. Clinical features of hypophosphatemia 
are widely varied, since numerous cellular mechanisms 
require phosphate (e.g., synthesis of adenosine triphosphate 
and 2,3-diphosphoglycerate). Hypophosphatemia is 
asso  ciated with leukocyte, erythrocyte, and platelet 
dysfunction; muscular weakness, confusion, ataxia, 
seizures and coma; respiratory failure; cardiac arrhythmias 
and cardiomyopathy.
Critically ill patients have underlying conditions that 
predispose them to developing hypophosphatemia, 
including malnutrition and inadequate body phosphorus 
stores, acute respiratory alkalosis, diabetic ketoacidosis, 
use of diuretics, alcoholism, and vomiting or gastric losses. 
Acute respiratory alkalosis can reduce plasma phosphate 
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glucose and the effect of hormones such as insulin, glu-
cagon, and cortisol can decrease plasma phosphate con-
centrations by redistribution into intracellular space. Re-
feeding and regenerative processes may result in severe 
hypophosphatemia because of phosphate uptake in anabolic 
tissue. Decompensated diabetes mellitus with ketoacidosis 
is associated with excessive phosphate loss due to osmotic 
diuresis. Administration of insulin, fluids, and correction 
of ketoacidosis may reveal phosphate deficiency and cause 
a sharp decrease in plasma phosphate concentration due to 
intracellular shift. 
Plasma phosphorus concentrations in critically ill 
pa  tients should be maintained within normal range 
(2.5–4.5 mg/dL), given the potential adverse effects of 
hypophosphatemia. Treatment of hypophosphatemia 
depends on the magnitude of hypophosphatemia and the 
presence of symptoms. Asymptomatic mild-to-moderate 
hypophosphatemia (1–2.5 mg/dL) can be treated with oral 
phosphate supplementation if the gastrointestinal tract is 
intact. Symptomatic or severe hypophosphatemia (< 1.0 
mg/dL) should be treated with intravenous phosphate. 
Plasma phosphate concentration < 0.5 mg/dL is associated 
with a phosphate deficit of more than 3 g; in the presence 
of symptoms, this deficit is more than 10 g
21). The required 
dose of initial intravenous phosphate may vary from 2.5 to 
19.8 mg/kg 
22). Typically, 2–5 mg/kg of inorganic phosphate 
dissolved in 0.45% saline is given over 6–12 hours and 
repeated as needed. Less than 50% of the initial dose 
should be given for patients who are not being treated with 
continuous renal replacement therapy (CRRT). Patients on 
CRRT should receive higher initial dosages, as the amount 
of phosphorus being removed by CRRT can be enormous. 
Further supplementation should be guided by clinical 
response to the initial doses and by plasma phosphate 
concentration.
Hypocalcemia
Hypocalcemia is one of the most frequent electrolyte 
abnormalities encountered in the ICU. Low total con-
centrations of calcium have been reported to be affecting 
as many as 90% of critically ill patients, and the prevalence 
of hypocalcemia measured as ionized calcium is estimated 
to be about 15–20%
23). Hypocalcemia is associated with 
increased mortality in patients cared in the ICU
24).
Most common causes of hypocalcemia include trauma, 
acute and chronic renal failure, sepsis, hypoparathyroidism, 
hypomagnesemia, vitamin D deficiency, and complexing 
with citrate, albumin, or infused phosphate. Dilution of 
plasma induced by administration of massive amounts of 
intravenous fluid in a resuscitative effort is reported to be 
an important cause of hypocalcemia in trauma patients
25). 
Decreased bone resorption, calcium chelation, calcitriol 
deficiency, decreased secretion or action of parathyroid 
hormone with or without hypomagnesemia, and increased 
urinary calcium excretion contribute to drug-induced 
hypocalcemia
9). Spuriously low concentration of calcium 
can be detected following the administration of gadolinium-
based contrast, as gadolinium interferes with calorimetric-
based calcium assays, while ionized calcium concentration 
measurements remain unaffected
26). 
The symptoms and signs of severe acute hypocalcemia 
include tetany, papilledema, and seizures. Chronic hypo-
calcemia causes neuropsychiatric manifestations such 
as emotional instability, basal ganglia calcification, and 
extrapyramidal disorders; skin manifestations such as 
brittle and grooved nails, hair loss, dermatitis, and eczema; 
and cardiovascular manifestations such as prolonged QT 
interval, ventricular arrhythmias, and congestive heart 
failure. 
Intravenous calcium should be given as calcium glu-
conate or calcium chloride to correct acute symptomatic 
moderate (total serum calcium concentration 7.5–8.0 mg/
dL) or severe (total serum calcium concentration < 7.5 
mg/dL or ionized calcium concentration < 0.9 mmol/
L) hypocalcemia. Calcium gluconate should be preferred 
for routine calcium maintenance and supplementation. 
Use of calcium chloride should be restricted to urgent and 
emergent situations, since calcium chloride provides three 
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Severe and symptomatic hypocalcemia requires urgent 
management. Initially, 1,000 mg of calcium chloride or 
3 g of calcium gluconate may be given over 10 minutes to 
control symptoms. Continuous infusion of calcium may 
be required, with close monitoring of serum calcium levels 
at least every six hours during the infusion. The infusion 
rate should not exceed 0.8–1.5 mEq/min because of the 
potential risk for cardiac arrhythmias. Typically, as an 
intermittent bolus dosage, 1–2 g of calcium gluconate is 
mixed in 100 mL of 5% dextrose or 0.9% sodium chloride 
and infused over 30 to 60 minutes. The dose may be 
repeated every 6 hours as needed until serum calcium levels 
have been normalized. 
Hypocalcemia is often accompanied by other electrolyte 
and acid-base disorders. Hypomagnesemia should be 
sought and corrected if hypocalcemia is not properly 
corrected by repeated calcium administration. Although 
the exact mechanism of calcium-magnesium interaction 
is unknown, it is hypothesized that magnesium deficiency 
may impair the release or activity of parathyroid hormone. 
When metabolic acidosis is present, hypocalcemia should 
be corrected before acidosis because the treatment of 
acidosis decreases the concentration of ionized calcium, 
thereby precipitating problems such as tetany or cardiac 
arrest. Bicarbonate solution and calcium salt should 
be administered in different intravenous lines to avoid 
precipitation of calcium carbonate. 
Chronic or asymptomatic hypocalcemia does not re-
quire intravenous calcium therapy. Concomitant hy-
perphosphatemia, especially in patients with renal 
fail  ure, requires phosphorus-lowering therapies. If hyper-
phosphatemia is not present, oral calcium supplements with 
or without vitamin D may be used. 
Hypomagnesemia
Hypomagnesemia is frequently observed in critically 
ill patients, and its prevalence in the ICU is reported to be 
as high as 50%
27). Severe hypomagnesemia can result in 
electrocardiographic changes, arrhythmias including torsades 
de pointes, seizures, coma, and death. Hypomagnesemia is 
associated with concomitant electrolyte disturbances such 
as hypokalemia and hypocalcemia. 
Causes of hypomagnesemia include excess gastro-
intestinal or renal losses, surgery, trauma, infection or 
sepsis, burns, transfusion of blood products preserved with 
citrate, alcoholism, starvation or malnutrition, and certain 
medications (e.g. diuretics, aminoglycosides, amphotericin 
B, cisplatin, digoxin, and cyclosporine). Fractional excretion 
of magnesium is a helpful index for differential diagnosis of 
hypomagnesemia
22). 
Serum magnesium concentration in critically ill pa-
tients should be maintained at 1.5 mg/dL or higher. 
Patients with acute myocardial infarction may require 
higher concentrations (i.e., > 1.7 mg/dL) to prevent fatal 
cardiac arrhythmias. The goals of therapy should be 
to avoid or resolve symptoms, return the serum mag-
nesium concentration to 1.5–2.4 mg/dL, and avoid 
hypermagnesemia. Serum magnesium levels do not reflect 
total body magnesium store, since only 1% of magnesium 
stores are found in the extracellular space. Although a study 
has reported that magnesium deficiency reflects a total 
body magnesium deficiency of 1.0–2.0 mEq/kg, treatment 
of hypomagnesemia is largely empirical and plasma [Mg
2+] 
should be carefully monitored. 
Intravenous administration is preferred in critically 
ill patients with severe (plasma [Mg
2+] < 1 mg/dL) or 
symptomatic hypomagnesemia. Infusion time is critical, 
because magnesium distributes into tissues slowly and 
is rapidly eliminated by renal excretion, with up to 50% 
of infused magnesium excreted in the urine. Severe 
hypomagnesemia requires treatment with 32–64 mEq 
(up to 1.5 mEq/kg) of magnesium. Doses less than 6 g of 
magnesium sulfate are infused over 8–12 hours, and higher 
doses are given over 24 hours. Reduced dose should be 
prescribed for patients with renal impairment to prevent 
hypermagnesemia. Mild hypomagnesemia can be treated 
with oral replacement. 80      JW Lee • Fluid and Electrolyte Disturbances in Critically Ill Patients
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Conclusion
Fluid and electrolyte abnormalities in critically ill 
patients can lead to fatal consequences. More caution to 
electrolyte disturbances should be exercised in intensive 
care because it is often impossible to adequately assess 
symptoms and signs of critically ill patients. To provide 
optimal management, clinicians should be knowledgeable 
about fluid and electrolyte homeostasis and the underlying 
pathophysiology of the respective disorders. In addition, 
intensivists should pay attention to the administered fluid 
and medications potentially associated with fluid and 
electrolyte disturbances. 
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